Mounting pressure to reduce the cost of R&D and boost
productivity has resulted in pharma companies undertaking radical
strategies as the search for efficiency continues. With the ongoing
patent cliff triggering a wave of patent expiries, pharmaceutical
R&D is at a turning point.
Features and benefits
As a short-term solution to increase profitability, the numerous companies have slashed their budgets, including R&D investment, but in the long term, downsizing may not prove to be sustainable, and as a result companies are placing a greater focus on collaborative R&D.
Externalization has become a core strategy in order to overcome R&D challenges, with companies opting to source their drug candidates via M&A, collaborations, licensing/co-development deals, venture capital investments, and partnerships with universities, spreading the cost and risk of drug development.
Pharma companies have re-evaluated their R&D pipelines in recent years, focusing on high growth, niche areas, while deprioritizing areas with low unmet meet. Consequently, leading pharma companies are focusing on developing candidates for secondary care indications while simultaneously reducing their efforts in primary care diseases.
Get Your Copy of Report @ http://www.reportsnreports.com/reports/160648-rd-trends-2012.html
Report Details :
Published: May 2012
Price: Single User License: US $ 5700 Corporate User License : US $ 14250
Table of Contents
EXECUTIVE SUMMARY
Introduction
Strategic scoping and focus
Key findings
R&D Productivity
Pharma’s Response
Strategies driving pharmaceutical sales growth out to 2016
Related reports
R&D PRODUCTIVITY
Improving return on investment remains a key challenge in terms of R&D
Increasing cost of R&D
Larger, longer, and more complex clinical trials drive up cost
Clinical trial success rates could improve by using adaptive trials
Decreasing R&D budgets
Big Pharma companies refocus their R&D pipeline in response to budget cuts
Issues with clinical trial recruitment
Collecting economic data in order to secure reimbursement approval is essential
Regulatory changes have a largely negative impact on pharma R&D
Greater focus on pharmacovigilance
US approval times could increase
US post-marketing studies may soon need to be conducted under direct supervision
Collaboration between the FDA and EMA is intensifying
Replacing sales from expiring blockbuster drugs will be a challenge
The number of drug approvals increased in 2011
PHARMA’S RESPONSE
Pharma uses externalization to drive growth
Pharma employs a range of external partnerships to boost R&D productivity
Partnerships with universities
Pfizer adopts the ultimate “open innovation” approach to cherry pick early-stage compounds
Venture capital investment
Sanofi targets early-stage research to stay ahead of the curve
Licensing
Licensing deals are increasingly focusing on milestone payments to minimize financial risks
Collaborations
Competitors become collaborators leading to the emergence of a novel combination therapies
M&A
Premiums rise in line with competition for acquisition targets
The line between licensing and M&A deals is blurring
Re-organization
Re-organization of business operations is spurred by challenging times
Bristol-Myers Squibb is divesting its ex-pharma units to increase operating margins and generate cash for a small acquisition
Outsourcing
Big Pharma enter preferred provider deals to improve outsourcing efficiencies
Spin-outs
GlaxoSmithKline readily turns to spin-outs in order to continue development of deprioritized projects
Abbott spins-out its pharmaceutical business to create new business opportunities
Features and benefits
- Provides an overview of the key R&D challenges facing pharma today as well as pharma’s solutions to alleviate these pressures.
- Trend analysis of R&D metrics, both industry wide and on a case-by-case basis for key Big Pharma companies.
- Insight into pharma’s R&D externalization strategies, supported by case study analysis.
- Case study analysis comparing and contrasting the performance and clinical pipelines AstraZeneca, Pfizer, Roche, and Sanofi.
As a short-term solution to increase profitability, the numerous companies have slashed their budgets, including R&D investment, but in the long term, downsizing may not prove to be sustainable, and as a result companies are placing a greater focus on collaborative R&D.
Externalization has become a core strategy in order to overcome R&D challenges, with companies opting to source their drug candidates via M&A, collaborations, licensing/co-development deals, venture capital investments, and partnerships with universities, spreading the cost and risk of drug development.
Pharma companies have re-evaluated their R&D pipelines in recent years, focusing on high growth, niche areas, while deprioritizing areas with low unmet meet. Consequently, leading pharma companies are focusing on developing candidates for secondary care indications while simultaneously reducing their efforts in primary care diseases.
Get Your Copy of Report @ http://www.reportsnreports.com/reports/160648-rd-trends-2012.html
Report Details :
Published: May 2012
Price: Single User License: US $ 5700 Corporate User License : US $ 14250
Table of Contents
EXECUTIVE SUMMARY
Introduction
Strategic scoping and focus
Key findings
R&D Productivity
Pharma’s Response
Strategies driving pharmaceutical sales growth out to 2016
Related reports
R&D PRODUCTIVITY
Improving return on investment remains a key challenge in terms of R&D
Increasing cost of R&D
Larger, longer, and more complex clinical trials drive up cost
Clinical trial success rates could improve by using adaptive trials
Decreasing R&D budgets
Big Pharma companies refocus their R&D pipeline in response to budget cuts
Issues with clinical trial recruitment
Collecting economic data in order to secure reimbursement approval is essential
Regulatory changes have a largely negative impact on pharma R&D
Greater focus on pharmacovigilance
US approval times could increase
US post-marketing studies may soon need to be conducted under direct supervision
Collaboration between the FDA and EMA is intensifying
Replacing sales from expiring blockbuster drugs will be a challenge
The number of drug approvals increased in 2011
PHARMA’S RESPONSE
Pharma uses externalization to drive growth
Pharma employs a range of external partnerships to boost R&D productivity
Partnerships with universities
Pfizer adopts the ultimate “open innovation” approach to cherry pick early-stage compounds
Venture capital investment
Sanofi targets early-stage research to stay ahead of the curve
Licensing
Licensing deals are increasingly focusing on milestone payments to minimize financial risks
Collaborations
Competitors become collaborators leading to the emergence of a novel combination therapies
M&A
Premiums rise in line with competition for acquisition targets
The line between licensing and M&A deals is blurring
Re-organization
Re-organization of business operations is spurred by challenging times
Bristol-Myers Squibb is divesting its ex-pharma units to increase operating margins and generate cash for a small acquisition
Outsourcing
Big Pharma enter preferred provider deals to improve outsourcing efficiencies
Spin-outs
GlaxoSmithKline readily turns to spin-outs in order to continue development of deprioritized projects
Abbott spins-out its pharmaceutical business to create new business opportunities
